Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1087

1.

High incidence of urinary tract infections after photoselective laser vaporisation of the prostate: a risk factor analysis of 665 patients.

Bausch K, Motzer J, Roth JA, Dangel M, Seifert HH, Widmer AF.

World J Urol. 2019 Oct 1. doi: 10.1007/s00345-019-02969-3. [Epub ahead of print]

PMID:
31578631
2.

Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: results from a multicentric surveillance cohort study.

Kern WV, Roth JA, Bertz H, Götting T, Dettenkofer M, Widmer AF, Theilacker C; Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS).

Transpl Infect Dis. 2019 Oct 1:e13186. doi: 10.1111/tid.13186. [Epub ahead of print]

PMID:
31574202
3.

Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries.

Halasz LM, Patel SA, McDougall JA, Fedorenko C, Sun Q, Goulart BHL, Roth JA.

PLoS One. 2019 Sep 30;14(9):e0222904. doi: 10.1371/journal.pone.0222904. eCollection 2019.

4.

Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component.

Corsini EM, Mitchell KG, Sceusi EL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL, Antonoff MB.

J Thorac Dis. 2019 Aug;11(8):3391-3398. doi: 10.21037/jtd.2019.08.20.

5.

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.

Schwartz NRM, Flanagan MR, Babigumira JB, Steuten LM, Roth JA.

J Manag Care Spec Pharm. 2019 Oct;25(10):1133-1139. doi: 10.18553/jmcp.2019.25.10.1133.

6.

Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells.

Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG.

Oncogene. 2019 Sep 25. doi: 10.1038/s41388-019-1010-4. [Epub ahead of print]

PMID:
31554935
7.

Reply to Yoshioka et al.

Roth JA, Widmer AF.

Clin Infect Dis. 2019 Aug 12. pii: ciz751. doi: 10.1093/cid/ciz751. [Epub ahead of print] No abstract available.

PMID:
31403167
8.

Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience.

Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL.

Dis Esophagus. 2019 Jul 17. pii: doz067. doi: 10.1093/dote/doz067. [Epub ahead of print]

PMID:
31313820
9.

Impact of health insurance status on surgical site infection incidence: A prospective cohort study.

Duggan BT, Roth JA, Dangel M, Battegay M, Widmer AF.

Infect Control Hosp Epidemiol. 2019 Sep;40(9):1063-1065. doi: 10.1017/ice.2019.195. Epub 2019 Jul 16.

PMID:
31309908
10.

Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy.

Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Morris VK, Antonoff MB.

J Surg Oncol. 2019 Sep;120(4):729-735. doi: 10.1002/jso.25630. Epub 2019 Jul 9.

PMID:
31290159
11.

Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.

Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B.

Cancer. 2019 Nov 1;125(21):3738-3748. doi: 10.1002/cncr.32366. Epub 2019 Jul 9.

PMID:
31287557
12.

Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization.

Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B.

Am J Cancer Res. 2019 Jun 1;9(6):1201-1211. eCollection 2019.

13.

Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.

Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, Roth JA, Antonoff MB; MD Anderson Lung Cancer Immune Microenvironment Working Group.

J Thorac Cardiovasc Surg. 2019 Sep;158(3):911-919.e6. doi: 10.1016/j.jtcvs.2019.04.084. Epub 2019 May 17.

PMID:
31235357
14.

Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.

Widmer AF, Kern WV, Roth JA, Dettenkofer M, Goetting T, Bertz H, Theilacker C; Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS).

Infection. 2019 Oct;47(5):837-845. doi: 10.1007/s15010-019-01327-0. Epub 2019 Jun 11.

PMID:
31187401
15.

An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.

Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA.

Cancer Immunol Res. 2019 Aug;7(8):1267-1279. doi: 10.1158/2326-6066.CIR-18-0874. Epub 2019 Jun 11.

PMID:
31186248
16.

Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.

Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B.

J Thorac Dis. 2019 Apr;11(4):1269-1278. doi: 10.21037/jtd.2019.04.27.

17.

Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.

Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Das P, Blum MA, Badgwell BD, Hofstetter WL.

Ann Thorac Surg. 2019 Sep;108(3):845-851. doi: 10.1016/j.athoracsur.2019.04.024. Epub 2019 May 15.

PMID:
31102632
18.

Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience.

Nelson DB, Mehran RJ, Mitchell KG, Rajaram R, Correa AM, Bassett RL Jr, Antonoff MB, Hofstetter WL, Roth JA, Sepesi B, Swisher SG, Walsh GL, Vaporciyan AA, Rice DC.

Ann Thorac Surg. 2019 Aug;108(2):370-376. doi: 10.1016/j.athoracsur.2019.03.051. Epub 2019 Apr 18.

PMID:
31004583
19.

Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?

Nelson DB, Mitchell KG, Weston BR, Betancourt S, Maru D, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Blum M, Hofstetter WL.

Dis Esophagus. 2019 Mar 19. pii: doz016. doi: 10.1093/dote/doz016. [Epub ahead of print]

PMID:
30888418
20.

Single-dose versus 3-day cotrimoxazole prophylaxis in transurethral resection or greenlight laser vaporisation of the prostate: study protocol for a multicentre randomised placebo controlled non-inferiority trial (CITrUS trial).

Speich B, Bausch K, Roth JA, Hemkens LG, Ewald H, Vogt DR, Bruni N, Deuster S, Seifert HH, Widmer AF.

Trials. 2019 Feb 19;20(1):142. doi: 10.1186/s13063-019-3237-3.

21.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR Jr, Lee JJ, Heymach JV, Zhang J.

J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16.

PMID:
30780001
22.

Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.

Kim MP, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.

J Thorac Dis. 2018 Dec;10(12):6670-6676. doi: 10.21037/jtd.2018.10.94.

23.

Medical diagnoses showed low relatedness in an explorative mutual information analysis of 190,837 inpatient cases.

Roth JA, Sakoparnig T, Neubauer S, Kuenzel-Pawlik E, Gerber M, Widmer AF, Hug BL; PATREC Study Group.

J Clin Epidemiol. 2019 May;109:42-50. doi: 10.1016/j.jclinepi.2019.01.003. Epub 2019 Jan 11.

24.

Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases.

Nelson DB, Tayob N, Mitchell KG, Correa AM, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Rice DC, Vauthey JN, Mehran RJ.

J Thorac Cardiovasc Surg. 2019 Apr;157(4):1648-1655. doi: 10.1016/j.jtcvs.2018.10.156. Epub 2018 Nov 26.

PMID:
30635188
25.

Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing.

Van Haren RM, Correa AM, Sepesi B, Rice DC, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Roth JA, Swisher SG, Antonoff MB.

Ann Thorac Surg. 2019 Mar;107(3):936-940. doi: 10.1016/j.athoracsur.2018.09.016. Epub 2018 Oct 26.

PMID:
30612991
26.

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.

Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B.

J Transl Med. 2018 Nov 26;16(1):328. doi: 10.1186/s12967-018-1704-3.

27.

A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer.

Zhang Y, Roth JA, Yu H, Ye Y, Xie K, Zhao H, Chang DW, Huang M, Li H, Qu J, Wu X.

Carcinogenesis. 2019 Jul 4;40(5):643-650. doi: 10.1093/carcin/bgy132.

PMID:
30428030
28.

Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.

Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng QH, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B.

Cancer Res. 2019 Jan 1;79(1):125-132. doi: 10.1158/0008-5472.CAN-18-1938. Epub 2018 Nov 6.

PMID:
30401714
29.

Introduction to Machine Learning in Digital Healthcare Epidemiology.

Roth JA, Battegay M, Juchler F, Vogt JE, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Dec;39(12):1457-1462. doi: 10.1017/ice.2018.265. Epub 2018 Nov 5. Review.

PMID:
30394238
30.

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).

Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV.

Clin Lung Cancer. 2019 Jan;20(1):43-47. doi: 10.1016/j.cllc.2018.09.015. Epub 2018 Sep 24.

PMID:
30343004
31.

Frequent Door Openings During Cardiac Surgery Are Associated With Increased Risk for Surgical Site Infection: A Prospective Observational Study.

Roth JA, Juchler F, Dangel M, Eckstein FS, Battegay M, Widmer AF.

Clin Infect Dis. 2019 Jul 2;69(2):290-294. doi: 10.1093/cid/ciy879.

PMID:
30321301
32.

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.

Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth JA, Zhou Q, Johnson DH, Swisher SG, Heymach JV, Papadimitrakopoulou VA, Xiao G, Minna JD, Wistuba II.

Clin Cancer Res. 2019 Jan 1;25(1):150-157. doi: 10.1158/1078-0432.CCR-17-2543. Epub 2018 Oct 4.

PMID:
30287547
33.

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.

Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P, Ramsey SD.

J Med Econ. 2018 Dec;21(12):1238-1245. doi: 10.1080/13696998.2018.1529674. Epub 2018 Oct 16. Erratum in: J Med Econ. 2018 Dec;21(12):1255.

PMID:
30260711
34.

Comment on "The domestic cat antibody responseto FHV-1 increases with age".

Roth JA.

Vet Immunol Immunopathol. 2018 Sep;203:65. doi: 10.1016/j.vetimm.2018.08.007. Epub 2018 Aug 20. No abstract available.

PMID:
30243376
35.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18.

PMID:
30228210
36.

Plea for Standardized Reporting and Justification of Propensity Score Methods.

Roth JA, Juchler F, Widmer AF, Battegay M.

Clin Infect Dis. 2019 Feb 1;68(4):710-711. doi: 10.1093/cid/ciy700. No abstract available.

PMID:
30137235
37.

Costs versus earnings in colon surgery and coronary artery bypass grafting under a prospective payment system: Sufficient financial incentives to reduce surgical site infections?

Juchler F, Roth JA, Schweiger A, Dangel M, Gugliotta M, Battegay M, Eckstein FS, Kettelhack C, Abshagen C, Hug BL, Boyce JM, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Oct;39(10):1246-1249. doi: 10.1017/ice.2018.179. Epub 2018 Aug 22.

PMID:
30131085
38.

Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women.

Nelson DB, Lapid DJ, Mitchell KG, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Nov;106(5):1499-1503. doi: 10.1016/j.athoracsur.2018.06.070. Epub 2018 Aug 15.

PMID:
30118712
39.

Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series.

Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B.

J Surg Oncol. 2018 Sep;118(3):518-524. doi: 10.1002/jso.25162. Epub 2018 Aug 15.

PMID:
30109699
40.

A qualitative study exploring patient motivations for screening for lung cancer.

Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ.

PLoS One. 2018 Jul 5;13(7):e0196758. doi: 10.1371/journal.pone.0196758. eCollection 2018.

41.

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.

Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Open Forum Infect Dis. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.

42.

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.

Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG.

Cancer Med. 2018 Jun;7(6):2405-2414. doi: 10.1002/cam4.1505. Epub 2018 Apr 19.

43.

Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients.

Sepesi B, Ye Y, Mitchell KG, Zhang L, Gu J, Ji L, Antonoff MB, Hofstetter WL, Rice DC, Mehran RJ, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Wu X.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2635-2645.e15. doi: 10.1016/j.jtcvs.2018.02.015. Epub 2018 Feb 15.

PMID:
29548588
44.

Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components.

Nelson DB, Godoy MCB, Benveniste MF, Shewale JB, Spicer JD, Mitchell KG, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jul;106(1):235-241. doi: 10.1016/j.athoracsur.2018.02.020. Epub 2018 Mar 11.

PMID:
29534957
45.

Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer.

Van Haren RM, Mehran RJ, Mena GE, Correa AM, Antonoff MB, Baker CM, Woodard TC, Hofstetter WL, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC.

Ann Thorac Surg. 2018 Jul;106(1):272-279. doi: 10.1016/j.athoracsur.2018.01.088. Epub 2018 Mar 9.

PMID:
29530770
46.

Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate.

Bausch K, Roth JA, Seifert HH, Widmer AF.

Swiss Med Wkly. 2018 Feb 23;148:w14594. doi: 10.4414/smw.2018.14594. eCollection 2018.

47.

Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer.

Mehran RJ, Martin LW, Roth JA.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1307. doi: 10.1016/j.jtcvs.2017.10.039. No abstract available.

PMID:
29452469
48.

Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer.

Shewale JB, Nelson DB, Rice DC, Sepesi B, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jun;105(6):1671-1677. doi: 10.1016/j.athoracsur.2018.01.031. Epub 2018 Feb 9.

PMID:
29432718
49.

Defect Rates in Touchless Versus Mechanical Hand Hygiene Dispensers.

Roth JA, Batzer B, Hug BL, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Mar;39(3):359-360. doi: 10.1017/ice.2017.306. Epub 2018 Jan 24. No abstract available.

PMID:
29363435
50.

TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.

Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, Baladandayuthapani V, Rice D, Sepesi B, Ji L, Roth JA.

Cancer Immunol Res. 2018 Feb;6(2):163-177. doi: 10.1158/2326-6066.CIR-17-0273. Epub 2018 Jan 16.

Supplemental Content

Support Center